prostatic neoplasms/vėmimas

Nuoroda įrašoma į mainų sritį

Pasirinkite rūšiavimo tipą

Puslapis 1 nuo 35 rezultatus

Cooperative clinical trials of the National Prostatic Cancer Project: Protocol 900.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

In May 1978, the National Prostatic Cancer Project Treatment Subgroup activated its first clinical trial evaluating adjuvant chemotherapy (Protocol 900). This protocol is a comparison of long-term adjuvant chemotherapy with cyclophosphamide, estramustine phosphate, or no additional treatment in

[Clinical effect of UFT on prostatic cancer].

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

A phase II study of UFT, a mixture of futraful and uracil in a rate of 1:4, was performed for prostatic cancer in 5 cooperative institutions. UFT was orally administered at a daily dose of 600 mg (t.i.d.) for 4 weeks. Twenty-two patients treated with UFT were evaluated according to Koyama-Saito's

[Phase I study of flutamide, a nonsteroidal antiandrogen, in patients with prostatic cancer].

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

A phase I study of orally administered flutamide (a pure anti-androgen) was performed in 26 patients with prostatic cancer. No side effects were observed in 11 patients receiving single doses of either 125, 250, 375 or 500 mg. However, in the daily dosing schedule of 375, 750, 1125 and 1,500 mg/day

Antiemetic efficacy of prednisolone: a placebo-controlled trial in patients with advanced prostatic cancer treated with estramustine phosphate.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

The antiemetic effect of prednisolone on nausea/vomiting was investigated in 67 patients with advanced prostatic cancer and a performance status of < or = 2. The study was a double-blind, placebo-controlled, randomized trial with a parallel group design. The objective was to compare the incidence

Leuprorelin acetate depot in advanced prostatic cancer: a phase II multicentre trial.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

The therapeutic efficacy and safety of various doses of leuprorelin acetate depot were determined in an open, multicentre study of patients with locally advanced or metastatic prostatic cancer (stages C, D1 or D2). Patients were randomly assigned to receive 3.75 mg (30 cases), 7.5 mg (eight cases),

[A trial of combination chemotherapy. Cis-platinum, peplomycin and adriamycin for advanced prostatic cancer].

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Between September 1982 and May 1984, combination chemotherapy with cis-platinum, peplomycin and adriamycin was administered to 12 patients with histologically confirmed adenocarcinoma of the prostate and progressive disease with evaluable parameters. Cis-platinum (CDDP) 20 mg/sqm was administered

[Chemoendocrine therapy of newly diagnosed advanced prostatic cancer].

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

From November 1981 to November 1987, 35 patients with newly diagnosed advanced prostatic cancer (6 Stage C cases and 29 Stage D2 cases) were treated by chemoendocrine therapy consisting of orchiectomy, diethylstilbestrol-diphosphate and cisplatin. Objective responses were assessed at 3 months after

[A case of subdural effusion secondary to dural metastasis of prostatic cancer: case report].

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

The authors reported a case of subdural effusion secondary to dural metastasis of prostatic cancer. A 61-year-old man was referred for headache, vomiting and gait disturbance. He had undergone hormonal therapy for prostatic cancer. He showed a mild left hemiparesis and anemia without bleeding.

Phase II study of cis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. 254-S Urological Cancer Study Group.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

A multicenter cooperative study was conducted to evaluate the clinical efficacy and safety of cis-diammine(glycolato)platinum (254-S), a second-generation anticancer platinum complex, in the treatment of genitourinary cancers. 254-S was given i.v. at 100 mg/m2 at 4-week intervals. As a result, 2

[Treatment of pain caused by metastases of reactivated prostatic cancer with ifosfamide].

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Ifosfamide (Z 4942) is an alkylating agent with the structure of a cyclophosphamide analog. Preliminary studies performed in our hospitals demonstrate the releasing effect of Ifosfamide for persistent pain caused by metastases of the prostatic cancer at various regions. Ifosfamide was given 2 grams

[Clinical evaluation of flutamide, a pure antiandrogen, in prostatic cancer phase II dose-finding study].

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

The phase II study of flutamide, a pure anti-androgen, was performed to estimate the clinical doses on 165 hormone untreated or treated patients with prostatic cancer. The hormone-untreated patients were given orally flutamide of 90, 375, 750 or 1,125 mg/day in three divided doses daily for 12

Prostatic cancer and SCH-13521: II. Histological alterations and the pituitary gonadal axis.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

We herein report on the results of treatment of 13 men with stage D prostatic carcinoma with a non-steroidal compound, SCH-13521 (flutamide). The dosage of the drug was 750 mg. in 3 divided doses daily and treatment extended for 2 to 20 months. Two patients failed to respond in any fashion, 7 had

Hemolytic-uremic syndrome during therapy with estramustine phosphate for advanced prostatic cancer.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

3 weeks after commencing treatment with estramustine phosphate, typical manifestations of hemolytic-uremic syndrome occurred in a 66-year-old patient with prostate cancer. Urinary tract obstructions were excluded and no renal damage could be identified. An improvement in renal function was achieved

High-dose ketoconazole therapy in prostatic cancer. A pilot study.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

There may be contraindications to oestrogen therapy for prostatic carcinoma, and also patient objections to orchidectomy as a form of therapy. Ketoconazole, a systemic antifungal drug, was evaluated in a dosage of 200 mg 8-hourly given orally as an alternative method of lowering serum testosterone

[High dose fosfestrol in phase I-II trial for the treatment of hormone-resistant prostatic adenocarcinoma].

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Androgen deprivation displays the mean therapy of advanced stage prostatic cancer, independently of palliative radiotherapy. The evolution to hormone-resistance status leads to a fatal tumor progression. High-dose fosfestrol (diethylstilbestrol diphosphate) has been suggested to circumvent

Ankstesnis
1
2
3
Kitas

Prisijunkite prie mūsų
„Facebook“ puslapio

Herbal & Natural Medicine

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu

Dirba 55 kalbomis
Žolelių gydymas, paremtas mokslu
Vaistažolių atpažinimas pagal vaizdą
Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
Skaitykite mokslines publikacijas, susijusias su jūsų paieška
Ieškokite vaistinių žolelių pagal jų poveikį
Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus

Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais